ArticleDiscover oncology2025
The causal relationship between immune cell phenotypes and esophageal cancer development: a bidirectional Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut Microbiota, Lipidome, and Metabolites Mediate Immune Dysregulation in Diabetic Microvascular Disease: A Two-sample Mendelian Randomization and Mediation Analysis.Endocrine, metabolic & immune disorders drug targets · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundImmune cell phenotypes have been implicated in the development and progression of esophageal cancer (EC), but their causal relationships remain unclear. This study aimed to explore the potential causal associations between immune cell traits and EC risk using Mendelian randomization (MR) analysis.
methodsA bidirectional two-sample MR analysis was conducted using genome-wide association study data from European populations. Genetic variants significantly associated with 731 immune cell phenotypes (P < 5 × 10
resultsSeven immune cell phenotypes were positively associated with an increased risk of EC, including SSC-A + on CD8 + T cells (P = 0.006), CD16 + monocytes (P = 0.013), and myeloid dendritic cells (P = 0.014). Conversely, CD3 + on HLA-DR + T cells (P = 0.017) and CD4 + T cell absolute count (P = 0.014) showed protective effects against EC. Sensitivity analyses confirmed these associations with minimal heterogeneity or pleiotropy. Reverse MR analysis found no evidence suggesting that EC causally influences immune cell phenotypes.
conclusionThis study provides genetic evidence supporting causal relationships between specific immune cell phenotypes and EC risk. Immune traits such as T cells, monocytes, and dendritic cells may serve as potential biomarkers or therapeutic targets for EC management. Further studies are needed to validate these findings and explore their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.